What’s Driving the Booming Market for Orphan Drugs

UNLIMITED

The Year in Biotech So Far and What’s Ahead: The biotech sector surged in the first half of the year despite volatile markets. M&A and financing continued to be robust as EvaluatePharma weighed in with its Pharma & Biotech Half-Year Report. We spoke to Jonathan Gardner, deputy news editor of EP... by The Bio Report

22 min listen

UNLIMITED

Reengineering Drug Discovery and Development: Drugmakers have employed new technologies to reduce the cost and time and it takes develop drugs and produce therapies that more precisely target the underlying biology driving diseases. Boston-based Berg Pharma is using artificial intelligence with ... by The Bio Report

21 min listen

UNLIMITED

Remembering Industry Pioneer Ron Cape by The Bio Report

27 min listen

UNLIMITED

What’s Driving the Booming Market for Orphan Drugs: The market for Orphan drugs is growing at more than twice the rate of other prescription medicines In 2013, a record 260 therapeutics won orphan designations in the United States alone as science, policy, and pricing are fueling the trend for drugmak... by The Bio Report

18 min listen

UNLIMITED

Brittany Maynard and the Debate over the Right to Die: Brittany Maynard, a 29-year-old woman with terminal brain cancer who chose to end her own life with a lethal dose of medication, sparked a renewed discussion of so-called death with dignity laws. Maynard had become visible on social and traditional m... by The Bio Report

23 min listen

UNLIMITED

Why Privacy Concerns May Limit Big Data’s Payoff: Two-thirds of Americans say they are willing to anonymously share their health information with researchers, but only about 1 in 5 is willing to provide their purchase history or social media activity, according to a recent Truven Health Analytics-NP... by The Bio Report

14 min listen

UNLIMITED

Enlisting Monoclonal Antibodies to Combat Bacterial Resistance: There’s growing global concern about threat from antibiotic resistant pathogens. That’s leading to new interest in looking beyond traditional antibiotics to monoclonal antibodies to address the problem. We spoke to Ken Stover, senior director of infe... by The Bio Report

21 min listen

UNLIMITED

The Lean Startup Takes Hold in the Life Sciences: The National Science Foundation and the National Institutes of Health, concerned about seeing the science they fund commercialized, have embraced the Lean Startup method as a way to improve the odds of success for new companies. Steve Blank, whose wo... by The Bio Report

23 min listen

UNLIMITED

Should Investors Temper Their Enthusiasm for CAR-T Therapies: CAR-T cell immunotherapies seek to harness the body’s immune system to fight tumor cells. The promise of this new class of therapies has ignited investor’s imaginations, but a new report from EP Vantage argues that the enthusiasm that has driven valu... by The Bio Report

24 min listen

UNLIMITED

Epirus Sees Opportunities for Biosimilars Outside U.S.: The regulatory pathway for biosimilars is still a work in progress at the U.S. Food and Drug Administration, but around the world the industry is growing as regulators have resolved issues that remain obstacles in the United States. We spoke to Amit ... by The Bio Report

18 min listen

UNLIMITED

International Collaboration Seeks to Drive Breakthroughs in Progressive MS: There has been dramatic progress in the understanding and treatment of relapsing remitting multiple sclerosis, a debilitating neurodegenerative disorder. But progressive MS, a more advanced form of the disease, has remained elusive. Now, a novel coll... by The Bio Report

24 min listen

UNLIMITED

A Look at the Year That Was in Biotech: The year 2014 was one for the record books for the biotech industry. In part one of a two-part podcast, we take a look back at the year that was with Adam Feuerstein, senior columnist for TheStreet.com. Feuerstein discusses the growing controversy ov... by The Bio Report

15 min listen

UNLIMITED

Calculating the Cost of Drug Development and What it Means: The cost of drug development, a metric that underlies discussions ranging from investment in startups to drug pricing, is a matter of great interest and controversy within the pharmaceutical industry. The Tufts Center for the Study of Drug Developmen... by The Bio Report

20 min listen

UNLIMITED

Will Policy Triumph Over Politics in 21st Century Cures Act: At the end of January, after nearly a year of hearings, roundtables, and white papers, the House Energy and Commerce Committee’s Subcommittee on Health released a draft of the much anticipated 21st Century Cures Act. The draft, nearly 400 pages long,... by The Bio Report

21 min listen

UNLIMITED

What Activist Investors Can Teach Biotech Companies: To improve the long-term value of biopharmaceutical companies, management should learn to think more like activist investors, according to a new report from EY. The report argues that capital allocation and strategic decision-making could benefit fro... by The Bio Report

16 min listen

UNLIMITED

Innovative Drugs Drive Big Increase in U.S. Spending: In April, the IMS Institute released a new report that U.S. drug spending in 2014 rose 13.1 percent to $373.9 billion, the largest single year increase in spending since 2001. A number of factors drove the increase including the launch of innovative ... by The Bio Report

20 min listen

UNLIMITED

Will Increased FDA Regulation of Diagnostics Speed or Slow Development of Personalized Medicine: The U.S. Food and Drug Administration is moving to expand its regulatory domain by adding oversight of certain diagnostics it does not regulate today. The agency says thousands of these test are used daily to guide treatment decisions and diagnose di... by The Bio Report

27 min listen

UNLIMITED

Why Interoperability Is Much More than a Technology Problem: A new government report finds that healthcare providers in the United States are increasing their adoption of health information technology, but their willingness to do so is tied to the incentives available. What’s more, the government is implementi... by The Bio Report

26 min listen

UNLIMITED

How One Company Is Reinventing Drug Development: Tomasz Sablinski believes the drug development process is broken and has sought to reinvent it. His company, Transparency Life Sciences, relies on crowdsourcing to design its clinical trials, makes all of its data public, and employs digital technolo... by The Bio Report

34 min listen

UNLIMITED

How One Foundation is Getting the Biggest Bang for Its R&D Bucks: As pressure on government and corporate research budgets grow, organizations like the Multiple Myeloma Research Foundation are playing an increasingly critical role in advancing and accelerating drug development. The foundation’s efforts, including i... by The Bio Report

28 min listen

UNLIMITED

Using Human Biology to Improve R&D: One problem with drug discovery and development is that answers about the way substances act in the human body are often not apparent early in the process. Though human cell assays have been used, they have their limitations. BioSeek’s BioMap technol... by The Bio Report

28 min listen

UNLIMITED

Examining the State of Sleep: Sleep researchers and clinicians will be gathering in Seattle June 6 - 10 for SLEEP 2015, a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. It is the largest gathering of sleep medicine physicians, sleep and ci... by The Bio Report

24 min listen

UNLIMITED

The Power of IBM’s Watson Is Coming to an App Near You: IBM’s Watson Group recently announced an investment in Pathway Genomics, part of a $100 million initiative by the computing giant to spur innovation in entrepreneurial companies that seek to leverage its cognitive computing platform Watson. Pathway G... by The Bio Report

18 min listen

UNLIMITED

Telemedicine Grows, but Reimbursement Remains an Obstacle: While many may think of telemedicine as an example of digital health technologies that will reshape the future landscape of medicine, a new survey from the law firm Foley & Lardner shows it is very much part of healthcare’s here and now. We spoke to ... by The Bio Report

22 min listen

UNLIMITED

Moving from Chronic Therapies to Cures: The rapidly growing area of regenerative medicine is promising to replace chronic therapies with cures. As the biotechnology industry gathers in San Francisco for a big week of meetings, the Alliance for Regenerative Medicine is readying to deliver i... by The Bio Report

22 min listen

UNLIMITED

Will Funding for Obama’s Precision Medicine Initiative Match Its Ambition: President Obama unveiled the details of his $215 million precision medicine initiative, the centerpiece of which is a 1 million person study that seeks to correlate genetic data, with health records, lifestyle information, and more to better understa... by The Bio Report

17 min listen

UNLIMITED

Reinventing Tech Transfer: Universities are moving away from a passive approach to technology transfer to engage with industry in new partnerships, put a greater emphasis on translational research, and nurturing technologies so they can give rise to new products and companies.... by The Bio Report

21 min listen

UNLIMITED

The Forces Bringing Disruptive Change to Healthcare: Scientific breakthroughs, innovations in technology, and the changing use of data are among the forces that are driving disruptive changes to healthcare. A new report from the IMS Institute for Healthcare Informatics highlights a number of these deve... by The Bio Report

21 min listen

UNLIMITED

Ensuring Digital Health Technologies Benefit Older People: AARP, the advocacy group serving people over the age of 50, is taking steps to ensure that digital health technologies best serve its membership. The organization has embarked on an initiative to test the design and functionality of digital health de... by The Bio Report

18 min listen

UNLIMITED

Democratizing the World of Healthcare Analytics: There’s no shortage of data created in the world of healthcare, but harnessing it to improve care and reduce costs remains a challenge. Apervita, backed with $18 million recent venture investment from GE Ventures, Baird Capital, and others is a mark... by The Bio Report

19 min listen

Discover this podcast and so much more

What’s Driving the Booming Market for Orphan Drugs

What’s Driving the Booming Market for Orphan Drugs

Description

Titles in the series (100)

More Episodes from The Bio Report

Related podcast episodes